上海莱士(002252) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was CNY 2,005,843,502.82, a decrease of 2.45% compared to CNY 2,056,305,681.88 in the same period last year[4] - Net profit attributable to shareholders decreased by 25.20% to CNY 566,082,988.41 from CNY 756,816,119.50 year-on-year[4] - The basic earnings per share fell by 25.44% to CNY 0.085 from CNY 0.114 in the previous year[4] - The company's total assets increased by 3.13% to CNY 34,682,214,928.65 compared to CNY 33,631,225,254.06 at the end of the previous year[4] - The company's weighted average return on equity decreased by 0.76 percentage points to 1.76% from 2.52% year-on-year[4] - The company's net profit from investments was CNY 90.35 million, down from CNY 268.70 million, indicating a decline of about 66.5%[28] - The net profit for the current period is CNY 566,224,805.20, a decrease of 25.3% compared to CNY 757,077,509.35 in the previous period[29] - The total comprehensive income for the current period is CNY 566,537,724.60, down from CNY 805,024,200.32 in the previous period, reflecting a decline of 29.6%[30] - Basic and diluted earnings per share are both CNY 0.085, compared to CNY 0.114 in the previous period, representing a decrease of 25.4%[30] - The operating profit for the current period is CNY 675,204,586.86, down from CNY 915,962,967.17 in the previous period, reflecting a decline of 26.2%[29] Cash Flow and Assets - Cash flow from operating activities improved by 3.29% to CNY 775,555,509.78 from CNY 750,871,567.39 year-on-year[4] - Cash inflow from investment activities totaled CNY 739,071,739.82, an increase from CNY 640,477,093.89 in the previous period[32] - The net cash flow from investment activities is CNY 192,997,880.61, compared to CNY 168,575,235.31 in the previous period, indicating a growth of 14.5%[32] - The net cash flow from financing activities is CNY 23,752,392.40, a significant improvement from a negative CNY 8,577,082.47 in the previous period[32] - The total cash and cash equivalents at the end of the period amount to CNY 2,327,563,555.98, down from CNY 4,107,317,479.17 in the previous period[33] - The company's cash and cash equivalents increased by 35.35% to CNY 4,037,081,864.80 from CNY 2,982,705,503.57 at the beginning of the period[8] Shareholder and Equity Information - The number of ordinary shareholders at the end of the reporting period was 107,443[10] - Haier Group will control a total of 1,875,224,208 shares of Shanghai Laishi, representing 28.25% of the company's total share capital, after the completion of the transaction with Grifols, S.A.[11] - As of April 7, 2025, Haier Group holds 1,438,154,552 shares of Shanghai Laishi, representing 21.67% of the total share capital[17] - The company plans to repurchase shares with a total amount not less than RMB 250 million and not exceeding RMB 500 million, with a maximum repurchase price of RMB 9.55 per share[12] - As of April 7, 2025, the company has repurchased a total of 15,649,851 shares, accounting for 0.24% of the total share capital, with a total transaction amount of RMB 108,426,420.12[14] - The first share buyback was completed with a total of 72,439,700 shares acquired, representing 1.09% of the total share capital, for approximately RMB 496.83 million[15] - The second share buyback plan aims to acquire shares with an amount not less than RMB 250 million and not exceeding RMB 500 million[16] - The maximum transaction price for the repurchased shares has not exceeded the upper limit set in the buyback plan[14] - The company has not disclosed any relationships among the other top 10 shareholders outside of the known entities[11] Research and Development - Research and development expenses decreased by 33.98% to CNY 33,065,109.12 from CNY 50,086,978.94 in the same period last year[9] - Research and development expenses decreased from CNY 50.09 million to CNY 33.07 million, a reduction of approximately 34%[28] - The company plans to enhance its product matrix through the integration of the target company's R&D resources, aiming to accelerate new product development[19] Acquisitions and Transactions - The company plans to acquire 100% equity of Nanyue Biological Pharmaceutical Co., Ltd. for a base price of RMB 4.2 billion, with an additional payment of RMB 50 million if the company achieves a plasma collection volume of 305 tons in 2025[18] - The acquisition will integrate the target company into Shanghai Laishi's consolidated financial statements, enhancing its plasma collection capabilities in Hunan Province[19] - After the transaction, Shanghai Laishi will operate 11 plasma collection stations and 1 branch in Hunan, becoming the market leader in blood products in the region[19] - Haier Group and Grifols, S.A. have agreed to a 36-month lock-up period for their respective shares following the completion of the transaction[11] Liabilities - The total liabilities rose from CNY 1.69 billion to CNY 2.17 billion, an increase of about 28.5%[25]